Virtu Financial’s Adverum Biotechnologies ADVM Stock Holding History

Virtu Financial’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,450	Closed	-$10K	–	1464
2023 Q1	$10K	Sell	1,450 -267	-16%	-$1.89K	﹤0.01%	1342
2022 Q4	$10K	Buy	+1,717	New	+$13K	﹤0.01%	1377
2021 Q3	–	Sell	-7,396	Closed	-$259K	–	1444
2021 Q2	$259K	Buy	+7,396	New	+$398K	0.03%	816
2021 Q1	–	Sell	-2,067	Closed	-$224K	–	1550
2020 Q4	$224K	Sell	2,067 -1,186	-36%	-$147K	0.02%	786
2020 Q3	$335K	Buy	3,253 +561	+21%	+$84K	0.06%	392
2020 Q2	$562K	Buy	+2,692	New	+$477K	0.06%	339
2019 Q4	–	Sell	-1,796	Closed	-$98K	–	1398
2019 Q3	$98K	Buy	+1,796	New	+$202K	0.01%	1089
2019 Q1	–	Sell	-2,086	Closed	-$66K	–	1373
2018 Q4	$66K	Buy	+2,086	New	+$84.9K	﹤0.01%	1225
2018 Q2	–	Sell	-2,012	Closed	-$117K	–	1937
2018 Q1	$117K	Buy	+2,012	New	+$125K	0.01%	1537
2017 Q4	–	Sell	-1,458	Closed	-$53K	–	2309
2017 Q3	$53K	Buy	+1,458	New	+$40.5K	﹤0.01%	2216

Other funds holding ADVM

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Virtu Financial's ADVM Position: Q2 2023 in Review

Virtu Financial sold out of Adverum Biotechnologies (ADVM) in Q2 2023, closing a stake of 1,450 shares — an estimated $10K sold.

Virtu Financial first reported a position in ADVM in Q3 2017 and held it in 10 quarters. The position peaked at $562K in Q2 2020. 57 funds tracked by Wall St. Rank hold ADVM as of Q2 2023.

Virtu Financial reported no remaining Adverum Biotechnologies position as of Q2 2023 after selling out during the quarter.
Virtu Financial sold 1,450 Adverum Biotechnologies shares in Q2 2023, an estimated $10K.
Virtu Financial first reported a position in Adverum Biotechnologies in Q3 2017 and held it in 10 quarters.
Virtu Financial's Adverum Biotechnologies position peaked at $562K in Q2 2020.
57 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2023.

Based on Virtu Financial's 13F filing for Q2 2023, filed 27 Jul 2023.